Navigating the procurement of high-purity synthetic secretagogues requires rigorous analytical verification, consistent lot-to-lot stability, and full transparency. This guide details the biochemical profile, pharmacological mechanisms, and quality verification standards for research laboratories evaluating GHRP-2 peptide acquisition.
Navigating the procurement of high-purity synthetic secretagogues requires rigorous analytical verification, consistent lot-to-lot stability, and full transparency. This guide details the biochemical profile, pharmacological mechanisms, and quality verification standards for research laboratories evaluating GHRP-2 peptide acquisition.
To acquire or buy ("kopen") research-grade GHRP-2 peptide online for laboratory study, institutional researchers require verifiable analytical documentation from an accredited supplier. GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide secretagogue evaluated strictly in vitro and in animal models to investigate pituitary somatotroph signaling, ghrelin receptor binding kinetics, and pulsatile hormone release dynamics.
When purchasing GHRP-2 online, investigators must prioritize suppliers providing independent, lot-specific documentation. Premium academic and industrial laboratories require Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) showing purity equal to or exceeding 98%, electrospray ionization mass spectrometry (ESI-MS) confirming exact molecular mass, and quantitative chromogenic Limulus Amebocyte Lysate (LAL) testing establishing low endotoxin thresholds. PX1 Research manufactures all research compounds in USA-based GMP-compliant facilities to support reproducible in vitro and preclinical research protocols.
GHRP-2, structurally designated as D-Phenylalanyl-D-beta-alanyl-L-alpha-aspartyl-L-phenylalanyl-L-lysine amide derivative (specifically D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2), is a synthetic hexapeptide designed to target the growth hormone secretagogue receptor (GHS-R1a). With a molecular formula of C45H55N9O6 and a molecular weight of approximately 817.97 g/mol, the compound exhibits distinct conformational stability compared to endogenous peptide ligands.
The D-amino acid substitution at key residues protects the peptide backbone against rapid enzymatic degradation by circulating endopeptidases in preclinical models. This structural modification enhances its receptor binding duration during in vitro assays. Researchers analyzing synthetic ligands across our full catalog of research peptides utilize these structural characteristics to model ligand-receptor interaction kinetics without the immediate metabolic degradation typical of un-modified native peptides.
GHRP-2 functions primarily as a potent agonist at the Growth Hormone Secretagogue Receptor type 1a (GHS-R1a), a G-protein coupled receptor (GPCR) abundantly expressed on somatotroph cells within the anterior pituitary gland and across specific hypothalamic nuclei. Preclinical studies suggest that upon receptor binding, GHRP-2 activates the phospholipase C (PLC) signal transduction pathway, driving the intracellular hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
The generation of IP3 triggers the rapid mobilization of intracellular calcium (Ca2+) ions from the endoplasmic reticulum into the cytosol. Concurrent activation of protein kinase C (PKC) by DAG facilitates the opening of voltage-dependent calcium channels, leading to an influx of extracellular calcium. This dual rise in intracellular calcium concentration stimulates the exocytosis of pre-stored growth hormone granules from pituitary somatotrophs. Unlike native growth hormone-releasing hormone (GHRH), which activates the cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) pathway, GHRP-2 operates via this distinct phosphoinositide signal cascade, allowing for additive signaling effects when co-administered in cell culture assays with classical GHRH analogs.
In vitro data indicate that GHRP-2 exhibits high affinity for GHS-R1a, demonstrating sub-nanomolar EC50 values in pituitary cell culture suspensions. Preclinical models utilizing isolated rat pituitary cells show a dose-dependent increase in peptide granule secretion upon exposure to GHRP-2 concentrations ranging from 0.1 nM to 100 nM. Because GHS-R1a receptors are also involved in central appetite signaling, preclinical rodent studies frequently measure feed intake responses alongside somatotropic signaling to map hypothalamic circuitry.
Additionally, academic literature highlights the role of GHRP-2 in exploring cardiac cell survival and anti-inflammatory pathways. In vitro assays evaluating myocardial cell cultures subjected to ischemia-reperfusion stress demonstrate that GHS-R1a activation by GHRP-2 attenuates oxidative stress markers and reduces apoptotic signaling through the activation of the Akt/ERK1/2 survival pathways. These research avenues continue to expand the scope of growth hormone secretagogues beyond neuroendocrine signaling alone.
Within secretagogue pharmacology, GHRP-2 is routinely evaluated alongside related synthetic peptides including GHRP-6, Ipamorelin, and Hexarelin. While all four compounds function as GHS-R1a agonists, their signaling selectivity, potency, and receptor desensitization profiles differ substantially in preclinical literature.
Comparative in vitro assays indicate that GHRP-2 possesses significantly higher potency at the GHS-R1a receptor than GHRP-6, requiring lower nanomolar concentrations to achieve equivalent intracellular calcium mobilization. However, unlike Ipamorelin—which exhibits high selectivity exclusively for somatotrope stimulation without altering secondary endocrine markers—GHRP-2 demonstrates mild cross-reactivity with adrenocorticotropic hormone (ACTH) and prolactin signaling pathways at higher concentration thresholds in rodent models. Hexarelin exhibits intense acute receptor binding but displays faster receptor desensitization kinetics than GHRP-2 during repeated exposure protocols in cell cultures. Detailed comparative methodologies are archived in our central peptide research hub for laboratory design optimization.
For research findings to achieve peer-reviewed reproducibility, raw materials must undergo strict analytical validation. PX1 Research subjects every synthesis lot of GHRP-2 to a multi-stage testing protocol conducted by independent ISO 17025 accredited testing facilities. Every vial shipped to academic or institutional laboratories is backed by verifiable, lot-traceable analytical documentation.
Primary purity analysis is established via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) using a C18 stationary phase and an acetonitrile/water gradient containing 0.1% trifluoroacetic acid (TFA). A compliant lot must demonstrate a single sharp peak area corresponding to greater than 98% purity, with all secondary micro-impurities accounted for and quantified. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the exact monoisotopic molecular mass of 817.97 Da, ensuring the complete absence of truncated peptide sequences or residual protecting groups. Furthermore, quantitative Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin levels remain strictly below 0.01 EU/mg, preventing confounding inflammatory responses in sensitive cell culture models.
GHRP-2 is supplied as a sterile, lyophilized (freeze-dried) powder to maximize chemical stability during transport and long-term storage. Unreconstituted vials stored at -20°C remain stable for up to 24 months when protected from light and moisture ingress. For short-term buffer handling prior to assays, lyophilized vials may be maintained at 2°C to 8°C for up to 90 days.
Reconstitution must occur within a certified laminar flow hood utilizing sterile laboratory technique. To preserve peptide integrity, researchers should reconstitute the lyophilisate using sterile bacteriostatic water or scientific-grade phosphate-buffered saline (PBS, pH 7.4). Diluent should be introduced along the glass vial wall rather than directly onto the lyophilized cake, followed by gentle swirl agitation—vigorous vortex mixing must be avoided to prevent mechanical shear stress and peptide denaturation. Post-reconstitution, liquid aliquots should be stored at -80°C to prevent freeze-thaw degradation cycles during long-term experimental series.
Acquiring analytical reagents for academic, biotechnology, or pharmaceutical research requires direct compliance with institutional procurement standards. PX1 Research facilitates seamless ordering workflows for university laboratories, government entities, and private R&D centers requiring commercial invoice matching, purchase order processing, and batch-specific validation.
Laboratories managing high-throughput screening projects or extended preclinical trials can access bulk inventory via our dedicated bulk research procurement channel. Every commercial shipment includes full lot documentation, material safety data sheets (MSDS), and certificates of analysis (COA) detailing HPLC chromatograms and mass spectra to satisfy institutional compliance audits.
GHRP-2 is supplied exclusively as a synthetic chemical reagent intended for in vitro research, analytical testing, and preclinical laboratory experimentation. It is explicitly not a drug, biological product, medical device, or dietary supplement, and is strictly prohibited for human or veterinary administration, clinical therapeutic use, or diagnostic procedures.
Handling personnel must possess proper biochemical training and utilize appropriate personal protective equipment (PPE), including nitrile gloves, eye protection, and laboratory coats. Waste streams containing synthetic peptides must be neutralized or disposed of according to institutional biohazard and chemical disposal guidelines. PX1 Research enforces strict buyer verification to ensure all materials are transferred exclusively to qualified research entities.
PX1 Research maintains an industry-leading supply infrastructure designed specifically to prevent supply chain disruption for critical research projects. All peptide synthesis, purification, lyophilization, and analytical packaging occur within state-of-the-art USA-based GMP-compliant facilities.
Orders placed before cut-off times ship same-day, Monday through Friday, directly from our centralized distribution hubs in California and Arizona. Utilizing controlled climate packaging and expedited logistics, PX1 Research eliminates transit degradation risks, ensuring that laboratories receive reagents adhering to exact analytical specifications. Explore our complete range of signaling analogs and secretagogues through our online catalog.
What is the certified purity standard for GHRP-2 from PX1 Research?
PX1 Research guarantees that every lot of GHRP-2 meets or exceeds 98% purity as measured by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Mass spectrometry (ESI-MS) reports are provided with every lot to confirm exact molecular identity.
How can researchers verify the Certificate of Analysis (COA) for GHRP-2?
Each GHRP-2 vial is assigned a unique lot number matching its physical packaging. Researchers can view and download the corresponding lot-specific COA, including complete HPLC chromatograms and mass spectral reports, directly from the PX1 Research website or by contacting lab support.
What are the endotoxin limits for PX1 Research GHRP-2?
Every synthesis lot undergoes chromogenic LAL assays to ensure endotoxin levels measure strictly below 0.01 EU/mg, preventing non-specific inflammatory signaling during sensitive in vitro assays and tissue culture protocols.
How should lyophilized GHRP-2 be stored upon arrival?
Lyophilized GHRP-2 should be stored at -20°C for long-term preservation (up to 24 months). If the material will be reconstituted within 30 to 90 days, cold storage at 2°C to 8°C is acceptable provided the vial remains sealed away from ambient moisture and light.
Which diluent is recommended for reconstituting GHRP-2 for in vitro assays?
Reconstitution is typically performed using sterile bacteriostatic water or scientific-grade phosphate-buffered saline (PBS, pH 7.4) under sterile laminar flow conditions. Researchers should avoid severe mechanical agitation to prevent peptide denaturation.
How does GHRP-2 differ mechanically from GHRP-6 and Ipamorelin in preclinical literature?
While all three compounds target the GHS-R1a receptor, GHRP-2 exhibits higher receptor binding affinity than GHRP-6. Ipamorelin demonstrates higher target selectivity without secondary ACTH or prolactin activation at elevated concentrations, whereas GHRP-2 exhibits minor secondary pathway signaling in specific preclinical models.
Where is PX1 Research GHRP-2 manufactured and shipped from?
All PX1 Research compounds are synthesized in USA-based, GMP-compliant facilities. Orders are dispatched directly from our optimized distribution centers in California and Arizona with same-day shipping available M–F.
Can GHRP-2 be ordered in bulk or custom quantities for institutional research?
Yes, PX1 Research supports institutional procurement, university supply agreements, and high-volume assay design through our wholesale procurement program, supplying custom vial sizes and dedicated batch reservations.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.